ApeX Omni has expanded its perpetual derivatives platform to include 125 markets, featuring 86 crypto contracts and 39 traditional finance (TradFi) contracts such as stocks, ETFs, and commodities. Traders can access all markets from a single USDT-margined account with adjustable leverage up to 100x for major cryptos and 50x for most other contracts. The platform supports cross-margined positions with multiple collateral options and separates crypto and TradFi margin pools to manage risk. ApeX Omni also provides advanced order types and integrates prediction markets and automated trading bots, aiming to combine centralized exchange speed with non-custodial security. This broad and flexible offering positions ApeX Omni as a unique venue for diverse perpetual trading opportunities.
ApeX Omni's expansion to 125 perpetual markets is noted here with Pluang's market data as of Sep 28, 2026 23:32 WIB. For readers following major cryptocurrencies, 11 of 50 priced rose and 38 fell today. Notable movers include ONE at Rp44 with a +8.74% change and a typical hold time of 152 days, EOS at Rp12,649 with +8.13%, and SNX at Rp4,327 with a -7.90% change and a strong buy order activity of 93%.
Vertex Pharmaceuticals reported a 12% revenue increase to $3.33 billion in Q2, driven by its dominant cystic fibrosis treatments. UBS raised its price target from $585 to $615, reflecting confidence in Vertex's strong financials and growth potential....
Accenture's stock surged 37.6% recently, driven by rising demand for AI services and new AI-focused offerings. The company outpaced industry growth and secured 100 new clients for advanced AI projects in one quarter. An analyst raised the price targe...
SpaceX, trading near $148 per share with a market cap of about $1.95 trillion, is preparing for Starship's first orbital mission and the deployment of its first operational Starlink V3 satellites. This milestone is key for expanding Starlink's global...
Argus Research initiated coverage on 10x Genomics with a Buy rating and a $110 price target, suggesting a 28% upside from its current price of around $85. The stock shows strong momentum, trading well above its 50-day and 200-day moving averages. How...
Morgan Stanley reaffirmed an "Overweight" rating on Cullen/Frost Bankers, Inc., raising its price target to $201, signaling confidence in the bank's prospects. Major institutional investors like State Street Corp and BlackRock have increased or initi...
